FBLG FibroBiologics, Inc.
FibroBiologics, Inc. (FBLG) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: March 4, 2026 , by O'HEERON PETE .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer | Buy | 30,000 | $0.38 | $11.4K | 61,250 | |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER | Buy | 15,872 | $0.38 | $6.0K | 5,958,147 | |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER | Buy | 18,200 | $0.41 | $7.4K | 5,942,275 | |
| Davis Jason | Chief Financial Officer | Buy | 70,000 | $0.41 | $29.0K | 70,000 | |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER | Buy | 17,428 | $0.35 | $6.2K | 5,924,075 | |
| GARCIA RUBEN A | General Counsel | Buy | 40,000 | $0.33 | $13.1K | 180,000 | |
| GARCIA RUBEN A | General Counsel | Buy | 140,000 | $0.34 | $47.6K | 140,000 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.